What is the FoCR HRD harmonization project? What is the purpose of this project?

Navigating the Maze: Friends of Cancer Research (FoCR) Tackles HRD Inconsistencies in Cancer Care

Imagine a powerful tool capable of identifying cancer patients who might benefit from specific, targeted treatments. This tool, the Homologous Recombination Deficiency (HRD) biomarker, holds immense promise in personalized cancer care. However, a major hurdle stands in the way – the lack of standardized methods for measuring and reporting HRD. This inconsistency leads to confusion and hinders the full potential of this valuable biomarker.

Why is standardization so important?

Think of HRD testing as navigating a maze. Without clear guidelines and consistent landmarks, it's easy to get lost. Different laboratories and testing platforms use different approaches, leading to varying results and confusion for both patients and healthcare professionals. This inconsistency makes it difficult to confidently identify patients who truly benefit from HRD-targeted therapies.

Enter the FoCR HRD harmonization project, a collaborative effort led by the Friends of Cancer Research (FoCR). This project brings together leading researchers, patient advocates, and diagnostic companies like ACT Genomics to tackle this critical issue. Their mission is to improve the agreement of different HRD testing methods and ultimately lead to.

• Improved patient identification: With accurate assessment, clinicians can confidently identify patients with HRD who are most likely to respond to specific treatments.
• Enhanced treatment selection: Standardized HRD testing will ensure patients receive the most appropriate and effective therapy based on their individual needs.
• Greater clinical confidence: Consistent testing methods will provide healthcare professionals with the clarity and confidence needed to make informed treatment decisions.

ACT Genomics: Leading the way with innovation

As a participant in the FoCR project, ACT Genomics brings its unique approach to the table and effectively measures the genomic loss of heterozygosity (gLOH), a key indicator of HRD. 

The FoCR project is a significant step forward for personalized cancer care. By addressing the challenges of HRD testing inconsistency, it has the potential to unlock the full potential of this valuable biomarker and improve outcomes for countless patients around the world.

Stay tuned: As the FoCR project progresses, we will continue to share its developments and insights. Remember, navigating the maze of cancer care is easier with a clear map, and the FoCR project is working hard to provide just that.

‍